Science Articles from the Newsletter
May 2008
Vol. 9, No. 5
· Interpreting research: dilemmas facing patients and physicians
· PI3Ks: a new target in GIST and new drugs in trials
· MRIs, CTs and PET scans examined and clarified
April 2008
Vol. 9, No. 4
· Call dissects 2007 LRG study
· April 2008 US clinical trial update
· Concerns raised, FDA meets on ESAs
· The doctor is in: common patient questions answered (Part Two)
March 2008
Vol. 9, No. 3
· Special Edition: The effect of imatinib dose upon the survival of metastatic GIST patients, an LRG study
February 2008
Vol. 9, No. 2
· The doctor is in: common patient questions answered
· Suboptimal response in CML linked to Gleevec uptake into leukemia cells
· February 2008 clinical trial update
· GI symposium offers interesting absracts
January 2008
Vol. 9, No. 1
· Molecular therapy and surgery combined in GIST
· January 2008 US clinical trial update
December 2007
Vol. 8, No. 12
· Apoptosis: How to kill a a GIST cell
· Dana Farber study focuses on wild-type kit and pediatric GIST
· December 2007 US & international clinical trial update
· Columbia researchers say CT scan overuse may lead to significant public health problem
· Opening of ‘Gleevec+IL2’ phase I trial at Gustave Roussy
· Kwart represents LRG at this year’s NORD conference
November 2007
Vol. 8, No. 11
· Looking for new ways to fight GIST
· November 2007 clinical trials update
· New views of receptor molecule may open doors
October 2007
Vol. 8, No. 10
· Building blocks of tumor progression
· October 2007 international clinical trials update
· Two reports of good Nexavar Response
· Carney-Stratakis syndrome explained
September 2007
Vol. 8, No. 9
· Pediatric GIST: an evolving concept
· NCCN task force takes strong stand in genotyping debate
· September 2007 clinical trial update
August 2007
Vol. 8, No. 8
· GIST Research Progress
· More highlights from ASCO 2007
· August 2007 clinical trial update
July 2007
Vol. 8, No. 7
· Looking for kinase mutations in GISTs: how, when and why?
· Highlights from ASCO 2007
· July 2007 clinical trial update
May 2007
Vol. 8, No. 5
· KIT & PDGFRA mutations in GIST: A to Z
· Clinical trial confirms Gleevec reduces recurrence
· Immunotherapy trial strives to improve Gleevec response
· Adjuvant Gleevec Q&A with Jonathan Trent and Jerry Call
· May 2007 clinical trial update
· AMN107 (Tasigna) now open at Fox Chase Cancer Center
April 2007
Vol. 8, No. 4
· Gene microarray technology yields interesting results in the laboratory
· April 2007 clinical trial update
· Novel KIT inhibitor also targets a new suspect; clinical trials to begin this year
· LRG works with medical institutions on Familial GIST study
· Simple two-gene test sorts out similar gastrointestinal cancers
March 2007
Vol. 8, No. 3
· The use of mouse models to help investigate GIST
· Immunotherapy: a new hope for GIST treatment
· Gleevec: revolutionizing GIST cancer treatment
· March 2007 clinical trial update
February 2007
Vol. 8, No. 2
· Understanding GIST survival under imatinib treatment
· Strategies and classes of potential GIST drugs
· February 2007 clnical trial update
January 2007
Vol. 8, No. 1
· Overcoming treatment resistance in GIST patients
· Questions to consider for adjuvant treatment
· January 2007 clnical trial update
December 2006
Vol. 7, No. 10
· European conferences attract GIST medical professionals
· Call comments on phase III Sutent results
· December 2006 clnical trial update
November 2006
Vol. 7, No. 9
· Connecting the Dots: Call offers perspective on GIST trends
· Researchers give update on GIST Resistance Project
· November 2006 clinical trial update
September 2006
Vol. 7, No. 8
· GIST studies receive substantial interest at ASCO '06 conference
· September 2006 clinical trial update
August 2006
Vol. 7, No. 7
· More placebo clinical trials predicted for cancer patients
· Life Raft reexamines the role of drug level testing
· Surgery and genotyping studies highlighted at ASCO conference
· AMG 706 will not get FDA approval for GIST
· Opinion on surgery for metastatic GIST
· Gleevec still beneficial, despite evidence of heart disease
July 2006
Vol. 7, No. 6
· Mutational testing predicts GIST treatment response
· Novartis-Schering drug vatalanib produces interesting early results
· Editorial: The time for routine mutational testing has come
· Life Raft meets with Infinity about IPI-504
· AMG706 continues testing as second line drug for Gleevec-resistant GIST patients
· ASCO reports Sutent as important drug for pediatric GIST
June 2006
Vol. 7, No. 5
· EORTC Study: Progression-free survival improves for 800 mg vs. 400 mg patients
· A continued discussion on optimizing therapy for GIST (View complete article by clicking here)
· June 2006 clinical trial update for GIST patients
· Highlights from the American Association for Cancer Research meeting
May 2006
Vol.
7, No. 4
· Understanding pediatric GIST may provide important clues
· May 2006 clinical trial update for GIST patients
March-April 2006
Vol.
7, No. 3
· Life
Raft funds 10 research
projects
· March
clinical trial update for
resistant GIST
· Optimizing
therapy for GIST: A
Discussion (View complete article by clicking here)
· Imatinib
resistance focus of intense
study
· Patient
status after four years on
Gleevec
February 2006
Vol.
7, No. 2
· Standard
treatment guidelines for
GIST
· Explosion
of GIST information raises
questions
· GIST
Q&A with Dr. Peter Reichardt
· A
roundup of clinical trials
January 2006
Vol. 7,
No. 1
· Sutent
given U.S. approval
· Challenges
ahead for the GIST community
· Infinity
launches trial of IPI-504
vs. GIST
December 2005
Vol. 6,
No. 9
· GIST
and Gleevec: 5 years of
progress
· Clinical
trial updates as of December
2005
November 2005
Vol.
6, No. 8
· Resistant
GIST may fall to new
inhibitor
· An
overview of CTOS 2005
September-October 2005
Vol.
6, No. 7
·
First strategic plan to
address treatment resistance
started
·
Life Raft members share
medical solutions
· Clinical
Trials target resistant GIST
July-August 2005
Vol.
6, No. 6
·
AMN107 + Gleevec clinical
trial opens
·
FDA fast-tracks approval
process for sutent
·
New insights to multi-drug
resistance
·
Questions and answers from
our members
June 2005
Vol.
6, No. 5
·
Advances reported at 2005
ASCO meeting
·
$2
million pledged for GIST
research
·
Sutent appears headed for
approval
·
AMG706 active vs. solid
tumors
·
PKC412 + Gleevec: stability
for some
April-May 2005
Vol.
6, No. 4
·
Beyond Gleevec: The next-era
drugs for GIST
·
Progress against GIST inches
ahead
·
Gleevec, vitamin C and
insulin slows disease
March 2005
Vol.
6, No. 3
·
Many drugs coming for
Gleevec-resistant GIST
·
PKC412 fights Gleevec-resistant
GIST
·
Druker updates stem cell
research
February 2005
Vol.
6, No. 2
·
SU11248 works, trial ends 7
months early
·
Why SU11248 works when
Gleevec fails
·
Leukemia researchers strive
for a cure
January 2005
Vol.
6, No. 1
·
Study: Gleevec levels
decrease over time
·
Fletcher tells Life Rafters
of new type of trial
·
U.S. agency puts AMG706 on
fast track
November-December 2004
Vol.
5, No. 11
·
Starting vs. actual dose
significant
·
Putting Gleevec tablets in
glycerin capsules raises
serious concerns
·
Life Raft Research Team
meets with European
researchers
·
A
Review of the posters and
papers at CTOS
·
Novartis scientists Review
Status of Drugs in Pipeline
October 2004
Vol.
5, No. 10
·
GIST mutation top cause
Gleevec failure
·
A
survival paradigm for GIST
September 2004
Vol.
5, No. 9
·
Glivec at higher doses
combats progression
August 2004
Vol.
5, No. 8
·
More study needed to
determine optimal Gleevec
dose
·
AMGEN launches phase II
clinical-No placebo
July 2004
Vol.
5, No. 7
·
New drug holds promise for
GIST's sister cancer
·
Update on new drugs with
GIST potential
June 2004
Vol.
5, No. 6
·
Cancer experts on GIST:
Gleevec dosage level is
still unresolved at the 40th
annual ASCO meet
·
What dose Gleevec is best
·
Pathologists predict
behavior of GIST
May 2004
Vol.
5, No. 5
·
GIST patients, experts meet
at Life Fest 2004
·
Pathologists share their
data on GIST
April 2004
Vol.
5, No. 4
·
AACR reports on drugs with
GIST possibilities
·
Higher doses of Gleevec work
best for CML
March 2004
Vol.
5, No. 3
·
Pediatric GIST collaboration
advances
·
Setting the record straight
February 2004
Vol.
5, No. 2
·
Gleevec vs. GIST trial at 3
years
·
Test to predict Gleevec
response expands
January 2004
Vol.
5, No. 1
·
U.S., Germany launch
‘Gleevec combo' trial
·
Novartis told of Gleevec
tablet side effects
November-December 2003
Vol.
4, No. 11
·
Placebo Use in Pfizer trial
raises fears
·
Lowering dose not advised
October 2003
Vol.
4, No. 10
·
Chicago area patients seek a
‘center of excellence'
September 2003
Vol.
4, No. 9
·
Loyola doctors focus on
STAT3 signaling
August 2003
Vol.
4, No. 8
·
Sugen offers option when
Gleevec fails
·
GIST patients see new
clinical trials
July 2003
Vol.
4, No. 7
·
Targets, targeted therapy
reports abound at AARC
·
Glivec Ok'd for GIST in
Japan, Israel
June 2003
Vol.
4, No. 6
·
Sugen drug an option if
Gleevec fails
·
Studies differ over 400 mg.
vs. 800 mg.
·
Gleevec tablets just as good
as capsules
·
Life Raft raises research
questions
·
Study: GIST can outwit
Gleevec four ways
·
Test reveals who'll respond
to Gleevec
May 2003
Vol.
4, No. 5
·
New drug outwits Gleevec
resistance
April 2003
Vol.
4, No. 4
·
Relapse survey: Is bigger
dose better?
March 2003
Vol.
4, No. 3
·
Researchers: Protein defect
linked to GIST
February 2003
Vol.
4, No. 2
·
Some observations on GIST
research and a tumor bank
January 2003
Vol.
4, No. 1
·
GIST patients help
researchers zero in on the
origins of cancer
December 2002
Vol.
3, No. 11
·
Sugen drug ‘surprisingly
effective' in early trials
·
Researchers find GIST more
common than once thought
November 2002
Vol.
3, No. 10
·
Life Raft gleens facts at
oncology meeting
·
Glivec-chemo combinations
warrant study
September 2002
Vol.
3, No. 8
·
Doctors hear of Life Raft
experience at London meet
July-August 2002
Vol.
3, No. 7
·
KIT remains the primary
target of GIST therapy
June 2002
Vol.
3, No. 6
·
UK
cost-cutting agency stalls
the use of Glivec
May 2002
Vol.
3, No. 5
·
Gleevec's effects are
lasting, researchers believe
April 2002
Vol.
3, No. 4
·
Early testing begins for new
GIST drug
February 2002
Vol.
3, No. 2
·
U.S. OK's Gleevec for GIST
January 2002
Vol.
3, No. 1
·
Gleevec on way to being No.
1 treatment for CML
November 2001
Vol.
2, No. 10
·
Novartis seeks U.S. OK to
use Gleevec on GIST
·
Glivec approved in European
Union for CML
October 2001
Vol.
2, No. 9
·
Life Raft patients report
fatigue is top side effect
September 2001
Vol.
2, No. 8
·
‘Glivec' moves closer to
European approval
July-August 2001
Vol.
2, No. 7
·
GIST researcher shares ‘our'
Gleevec experience
June 2001
Vol.
2, No. 6
·
Life Raft patients share
responses, side effects
May 2001
Vol.
2, No. 5
·
Gleevec OK'd by FDA;
effectiveness hailed
·
‘Off label' use worries
Gleevec researchers
·
Journal reports on clinical
trial patient No. 1
April 2001
Vol.
2, No. 4
·
Real Progress with real
people, thanks to the global
community
·
Survey: Gender plays role in
side effects
March 2001
Vol.
2, No. 3
·
STI571 notes from leukemia
group at OHSU
·
Novartis files globally for
approval of Glivec
February 2001
Vol.
2, No. 2
·
The fast-track story of
STI571
January 2001
Vol.
2, No. 1
·
Glivec resistance a concern;
optimism prevails
·
New NCI-sponsored clinic
trial of STI571 for GIST
*This is an attempt to help you find all the science articles in our newsletters. Be aware that some of the info will change over time.
